ABBV-1758 is positioned within a competitive landscape of Alzheimer's disease therapies, particularly in the context of anti-amyloid treatments. Given the increasing prevalence of Alzheimer's and the unmet medical need for effective therapies, ABBV-1758 could capture significant market share if proven effective. The trial's design includes diverse populations (U.S., China, Japan), which may enhance its global market potential. However, the treatment burden on participants may impact recruitment and retention, necessitating careful management. The results of this trial will be critical in determining AbbVie's strategic positioning in the Alzheimer's market, especially against other emerging therapies.